Sites: CDL-Montreal, CDL-Seattle, CDL-Toronto, CDL-Wisconsin
Streams: Artificial Intelligence, Health, Neuro
Milad Alucozai invests in early-stage bio, healthcare, and deep technology companies. He is a Venture Partner at Entrepreneur First, a global fund with a portfolio value of over $4 billion. In 2020, he was appointed as an External Advisor to AstraZeneca (NASDAQ:AZN), working on initiatives to partner more closely with startups. He has also served as an advisor to startups like Numerate, a San Francisco-based drug discovery company (acquired by Valo Health), and Absci, a Vancouver-based AI-powered synthetic biology company that recently went public (NASDAQ: ABSI). He proudly serves as a Mentor for groups like the Creative Destruction Lab and Harvard University iLabs.
Milad’s career began as a bench scientist working in translational neuroscience and multiphysics labs. He transitioned into becoming a founder and part of the founding team of multiple healthcare and bio startups. He is part of the founding team at Mekonos, a San Francisco-based company building a platform for cell delivery supporting the future of cell and gene therapies. Prior to this, he served as CBO at Corstem, a company specializing in machine learning and artificial intelligence software (acquired by Circle Cardiovascular, a platform used in over 1000 hospitals and in more than 40 countries). During his time at Accenture, Milad led data scientists, designers, and engineers focused on building AI products for global pharmaceutical companies and hospital networks.
He is a former Visiting Scholar in Healthcare Engineering at the Regenstrief Center. He was a National Science Foundation Scholar and Macklin Fellow at Johns Hopkins Medicine and graduated Phi Beta Kappa with a degree in Neuroscience from Purdue University’s Honors Program. As a George J. Mitchell Scholar, he completed graduate school in Immunology & Public Health.